Gilead opting against IDE397 is still good news for Ideaya.
ApexOnco Front Page
Recent articles
Progression-free and overall survival data from Companion-002 are due this quarter.
Opdivo and Yervoy succeed again, but the US path remains unclear.
The company reveals fresh biopsy status as a primary endpoint, and declares Aspen-06 a win.
The company might need something better to replace its ageing blockbuster.
Poor efficacy clouds prospects for the company's "improved" Yervoy.
While Cogent joins the FGFR party.
Just when investors thought things couldn't get any worse, they do.
